TGFB1 and colorectal cancer: Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐stage tumoroids susceptible to TGF‐β treatment and induced partial EMT and increased invasion.